--- title: "CJC-1295 with DAC: Dosage, Side Effects & Prices" url: https://www.bodyhackguide.co/compound/cjc-1295-dac description: "CJC-1295 with DAC: dosing protocols, mechanism & side effects, 33 PubMed results. Compare 4 current vendor prices." lang: en --- Skip to content Compare notes on r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Compare notes with other researchers. Join r/BodyHackGuide (https://reddit.com/r/bodyhackguide) # CJC-1295 with DAC Growth Hormone / IGF-1 Axis: https://www.bodyhackguide.co/wiki#cat-growth-hormone-/-igf-1-axis Status Phase 2,, not approved for human use Evidence Not graded on a research bench yet CJC-1295 with DAC (Drug Affinity Complex) is a modified form of CJC-1295 that incorporates a maleimidopropionic acid (MPA) reactive group at the C-terminus. Reviewed 2 October 2026 01 Overview ## What CJC-1295 with DAC is Once injected, this MPA group forms a **covalent thioether bond with free cysteine residues on serum albumin**, effectively turning the small peptide into a long-circulating albumin-peptide conjugate. Read the full overview Show less The pharmacokinetic consequence is dramatic. Native GHRH has a half-life of <2 minutes. MOD-GRF 1-29 (CJC-1295 without DAC) has a half-life of ~30 minutes. **CJC-1295 with DAC has a half-life of ~8 days** and produces sustained IGF-1 elevation for up to 28 days after a single injection (Teichman et al., 2006, _J Clin Endocrinol Metab_ (https://pubmed.ncbi.nlm.nih.gov/16352683/)). This makes DAC the **weekly-dosing variant**: one subcutaneous injection of 1-2 mg per week, typically on the same day each week. Convenience is its headline advantage over MOD-GRF 1-29's 2-3x daily injections. The trade-off is physiologic. DAC produces **continuous, non-pulsatile GH elevation** rather than the sharp pulses of natural secretion or MOD-GRF 1-29. In Teichman's Phase 1 trial, mean GH levels at 60 mcg/kg rose 2-10 fold above baseline and **remained elevated continuously for 6-14 days** after a single injection, with IGF-1 rising 1.5-3 fold and staying elevated for up to 28 days with repeated weekly dosing. This is an efficient way to raise IGF-1 but is not how the body normally operates. Clinical development was halted at Phase 2 — ConjuChem Biotechnologies did not publicly detail the reason, though industry commentary has pointed to concerns about sustained non-pulsatile GH elevation, insulin resistance, and the general challenges of bringing a GH-axis drug to market. Tesamorelin (a shorter-acting GHRH analog) became the FDA-approved GHRH analog for HIV-associated lipodystrophy instead. CJC-1295 with DAC is **not FDA-approved** and is used research-only or through compounding pharmacies. It is the less-favored of the two CJC-1295 forms in modern clinical protocols; most practitioners now prefer MOD-GRF 1-29 (without DAC) stacked with ipamorelin for the more physiologic pulsatile profile. See /compound/cjc-1295 (https://www.bodyhackguide.co/compound/cjc-1295) for the non-DAC variant, and our Reconstitution Tool (https://www.bodyhackguide.co/tools/reconstitution/cjc-1295) for injection math. ### How it works CJC-1295 with DAC has the **same pharmacodynamic mechanism** as the non-DAC variant (GHRH receptor agonism on pituitary somatotrophs) but radically different pharmacokinetics. Read the full mechanism Show less **1. Albumin conjugation - the central pharmacokinetic feature** - The MPA (maleimidopropionic acid) group is highly reactive toward free thiol groups - Serum albumin contains one free cysteine (Cys-34) per molecule - Within hours of SC injection, CJC-1295 DAC forms a **covalent thioether bond with Cys-34 on serum albumin** - The conjugate circulates for the full albumin half-life (~20 days) - Effective drug half-life: **~8 days** (shorter than albumin because GHRH portion is slowly cleaved/metabolized) **2. Sustained GHRH-receptor activation** Because the albumin-bound conjugate keeps GHRH-active peptide in circulation for days, the pituitary GHRH receptor is **continuously exposed to ligand** rather than to brief, widely spaced pulses. Critically, this does **not** abolish pulsatile GH release: in the controlled pharmacodynamic work, pulsatile GH secretion _persisted_ during continuous stimulation with CJC-1295 (Ionescu & Frohman, 2006, _J Clin Endocrinol Metab_). What shifts is the baseline - DAC raises **trough (basal) and mean GH** concentrations while the underlying pulse frequency is largely preserved. The practical consequences: - Higher basal and mean GH, with pulsatility retained rather than eliminated - A sustained **IGF-1 plateau** rather than the sharp IGF-1 swings of short-acting secretagogues - A theoretical risk of partial receptor desensitization with chronic, continuous exposure **3. Pharmacokinetic profile (Teichman Phase 1 data)** Single 60 mcg/kg SC dose: - GH levels: 2-10x baseline, sustained for 6-14 days - IGF-1: 1.5-3x baseline, sustained for up to 28 days with repeated weekly dosing - IGFBP-3 proportionally elevated **4. No direct ghrelin-receptor activity** DAC does not bind GHS-R1a. If stacking with ipamorelin is desired, the two must be dosed separately - DAC weekly, ipamorelin daily. Many practitioners skip ipamorelin when using DAC because the sustained GH elevation already approaches pituitary capacity. **5. Downstream IGF-1 axis effects** - Hepatic JAK2/STAT5 signaling produces sustained IGF-1 mRNA transcription - IGFBP-3 rises proportionally (binds 90% of circulating IGF-1) - Free (bioactive) IGF-1 rises modestly - Tissue IGF-1 (muscle, bone, cartilage) rises more substantially **6. What's different vs MOD-GRF 1-29 (without DAC)** | Parameter | CJC-1295 DAC | MOD-GRF 1-29 | | --- | --- | --- | | Half-life | ~8 days | ~30 min | | GH profile | Raised basal GH, pulses preserved | Discrete pulses, low basal | | IGF-1 magnitude | 1.5-3x baseline | 1.5-2x baseline | | Dose frequency | Weekly | 2-3x daily | | Receptor desensitization risk | Higher | Lower | | Physiologic mimicry | Lower | Higher | | Ipamorelin synergy | Limited (timing mismatch) | Strong | This is why modern protocols favor the non-DAC form despite its inconvenience. ### Studied for - Growth hormone axis - Long-acting peptide therapeutics - Body composition - Anti-aging medicine - Albumin-drug conjugation chemistry - Endocrinology - Compounding pharmacy ### Benefits listed - Sustained IGF-1 elevation (1.5-3x baseline) for 28+ days - Convenient weekly subcutaneous dosing - Improved body composition (lean mass, fat loss) - Enhanced recovery from training and injury Show 6 more Show less - Albumin conjugation extends half-life to ~8 days - Stimulates endogenous GH production vs exogenous replacement - Dose-dependent GH elevation 2-10x baseline - Phase 1 clinical data in 50 healthy adults (Teichman 2006) - Useful in compounding pharmacy GH-axis protocols - Single-agent convenience vs combination peptide protocols 02 Research Free with email ## What the research shows No research bench grades CJC-1295 with DAC yet. Benches compare compounds people pair, with the evidence for each. ### Unlock the research summary Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser. - A summary of the key research - Safety and side effects - A link to the PubMed results You also get the free peptide cheat sheet by email. Unsubscribe anytime. Have an account? Sign in (https://www.bodyhackguide.co/auth) 03 Safety ## CJC-1295 with DAC side effects and interactions ### Side effects Low risk Stop use if - Active malignancy - Pituitary disorders - Uncontrolled diabetes #### Common - Water retention - Headache - Injection site reactions - Increased appetite #### Less common - Elevated blood glucose - Joint pain - Carpal tunnel symptoms ### Who should not use it Contraindications **Absolute contraindications** - **Active malignancy of any type** — sustained IGF-1 elevation is a stronger pro-tumorigenic concern than with pulsatile MOD-GRF 1-29 - **History of cancer within 5 years** — relative; discuss with oncologist - **Diabetic retinopathy (active or history)** - **Pregnancy and lactation** - **Children with open growth plates** - **Critical illness requiring ICU care** — Takala 1999 signal of increased mortality with sustained GH - **Severe uncontrolled type 2 diabetes (HbA1c >8)** — sustained GH worsens glucose Read all the contraindications and cautions Show less **Relative contraindications** - Controlled type 2 diabetes — use non-DAC form preferentially - Obstructive sleep apnea - Severe hypothyroidism - Intracranial pathology - Family history of acromegaly or pituitary adenoma **Drug interactions** - **Glucocorticoids** — may blunt response; minimize - **Somatostatin analogs** — direct GH suppression; incompatible - **Insulin / insulin secretagogues** — counter-regulatory; monitor glucose - **Oral estrogens (high-dose)** — blunt hepatic IGF-1 response - **Chemotherapy agents** — avoid concurrent use **Surgery considerations** - Hold 2-3 weeks before elective major surgery (due to longer washout) - Disclose to all clinicians, especially oncology, endocrinology, ophthalmology - Washout from DAC is 3-4 weeks due to ~8-day half-life plus albumin half-life **WADA prohibition** - GH-releasing peptides prohibited at all times for competitive athletes - Urine testing can detect GH-axis manipulation via GH isoform ratios and IGF-1 measurements **Disclosure obligations** - All clinicians - Insurance applications (material in some jurisdictions) - Workers' compensation / disability evaluations **Cannot be rapidly reversed** Because of the 8-day half-life and 3-4 week washout, CJC-1295 with DAC cannot be rapidly discontinued in response to an acute side effect or contraindication change. Users and clinicians must be prepared for this. ### Interactions 4 pairings in our record: 2 to avoid, 1 with a caution and 1 noted as compatible or synergistic. Compatible and synergistic are notes from the record, not safety findings. - CJC-1295 (no DAC) Avoid Redundant GHRH analogs — the DAC version provides sustained release, do not stack - Sermorelin Avoid Redundant GHRH mechanism — pick one - MK-677 Caution Both provide sustained GH — risk of excessive GH/IGF-1 levels - Ipamorelin Synergistic Common combination for sustained GH elevation This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. Order Bloodwork (https://anabolicinsights.ai/?ref=nwm2zjb) 04 Dosing Free with email ## CJC-1295 with DAC dosage and protocols Dose range 1,000–2,000 mcg (1–2 mg) per injection Dosing Once per week Common vials 2mg, 5mg ### Unlock the dosing protocols - Dose, route, how often and how long - A titration schedule - Beginner, intermediate and advanced protocols - Reconstitution and handling notes 05 Prices ## CJC-1295 with DAC prices 6 listings from 4 vendors, opening in the Featured order. Pack prices $34.99 to $59.00 Lowest per mg $8.00/mg Vendors 4 Listings 6 (vial) Prices as the vendors list them, last recorded 27 October 2026. Size Form Sort | Vendor | Product | Price | Buy | | --- | --- | --- | --- | | Image: Disguised Alpha logo (https://disguisedalpha.com/wp-content/uploads/2026/10/disguised-logo-3x.webp) Disguised Alpha: https://www.bodyhackguide.co/vendors/disguised-alpha | CJC-1295 with DAC vial, 1 vial Out of stock | $59.99 No mg count | View CJC-1295 with DAC at Disguised Alpha: https://disguisedalpha.com/product/cjc-1295-drug-affinity-complex/?coupon=reddit | | Image: Ion Peptide logo (https://ionpeptide.com/wp-content/uploads/2025/08/ion-peptide-logo-1-300x148.jpg) Ion Peptide: https://www.bodyhackguide.co/vendors/ion-peptide | CJC-1295 With DAC 5mg vial, 1 vial In stock | $11.80/mg $59.00 | Buy CJC-1295 With DAC 5mg at Ion Peptide: https://ionpeptide.com/product/cjc-1295-with-dac-5mg/?ref=reddit15 | | Image: BioMyst Labs logo (https://biomyst-labs.com/wp-content/uploads/2025/12/Asset-36@3x-scaled.png) BioMyst Labs: https://www.bodyhackguide.co/vendors/biomyst-labs | CJC-1295 w/ DAC 5mg vial, 1 vial In stock | $8.00/mg $39.99 Lowest per mg | Buy CJC-1295 w/ DAC 5mg at BioMyst Labs: https://biomystlabs.com/product/cjc-w-dac-5mg/?ref=rxtkqorwv | | Image: BioMyst Labs logo (https://biomyst-labs.com/wp-content/uploads/2025/12/Asset-36@3x-scaled.png) BioMyst Labs: https://www.bodyhackguide.co/vendors/biomyst-labs | CJC-1295 w/ DAC 5mg vial, 1 vial In stock | $9.00/mg $44.99 | Buy CJC-1295 w/ DAC 5mg at BioMyst Labs: https://biomystlabs.com/product/cjc-w-dac-5mg/?ref=rxtkqorwv | | Image: Half Nattys logo (https://halfnattys.is/wp-content/uploads/2026/09/cropped-Untitled-design-14.png) Half Nattys: https://www.bodyhackguide.co/vendors/halfnattys CHON | CJC w/ DAC 2mg vial, 2mg vial In stock | $17.50/mg $34.99 | Buy CJC w/ DAC 2mg at Half Nattys: https://halfnattys.is/product/cjc-w-dac-5mg/?ref=choncho | | Image: Half Nattys logo (https://halfnattys.is/wp-content/uploads/2026/09/cropped-Untitled-design-14.png) Half Nattys: https://www.bodyhackguide.co/vendors/halfnattys CHON | CJC w/ DAC 5mg vial, 5mg vial In stock | $10.00/mg $49.99 | Buy CJC w/ DAC 5mg at Half Nattys: https://halfnattys.is/product/cjc-w-dac-5mg/?ref=choncho | Vendors selling CJC-1295 with DAC(4: trust score, certificates, payment, shipping) - Half Nattys (https://www.bodyhackguide.co/vendors/halfnattys)2 listings, from $34.99 Trust Score 50/100 (https://www.bodyhackguide.co/vendor-trust-scorecard), 0 of 31 certificate records read, pays by card, crypto, Zelle, ships to the US - BioMyst Labs (https://www.bodyhackguide.co/vendors/biomyst-labs)2 listings, from $39.99 Trust Score 70/100 (https://www.bodyhackguide.co/vendor-trust-scorecard), no certificate records on file, pays by card, crypto, ships to the US, international destinations - Ion Peptide (https://www.bodyhackguide.co/vendors/ion-peptide)1 listing, from $59.00 Trust Score 70/100 (https://www.bodyhackguide.co/vendor-trust-scorecard), no certificate records on file, pays by card, crypto, ACH, ships to the US, international destinations - Disguised Alpha (https://www.bodyhackguide.co/vendors/disguised-alpha)1 listing, from $59.99 Trust Score 50/100 (https://www.bodyhackguide.co/vendor-trust-scorecard), 0 of 36 certificate records read, pays by card, crypto, bank transfer, ships to the US, the EU, the UK Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. How we score these vendors (https://www.bodyhackguide.co/vendors/scorecard) Price history(4 days with a recorded price) Review CJC-1295 with DAC ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with CJC-1295 with DAC. 06 Chemistry ## Chemistry and structure Molecular formula C165H269N47O46 Molecular mass 3647.1 g/mol CAS number 446262-90-4 IUPAC name CJC-1295 with Drug Affinity Complex Amino acid sequence Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys-NH2 - a 30-residue tetra-substituted analog of human GRF(1-29): [D-Ala2, Gln8, Ala15, Leu27] substitutions (the "modified GRF 1-29" backbone), plus a C-terminal Lys30 bearing a maleimidopropionyl (MPA) "DAC" linker that forms a covalent thioether bond with Cys-34 of serum albumin. View on PubChem (https://pubchem.ncbi.nlm.nih.gov/compound/91971820) 07 Related ## Related to CJC-1295 with DAC ### In the same category - CJC-1295 (Mod GRF 1-29)Preclinical CJC-1295 without DAC (also called Modified GRF 1-29 or MOD-GRF 1-29) is a 29-amino-acid analog of the N-terminal fragment of endogenous Growth Hormone Releasing Hormone (GHRH), with four strategic substitutions (D-Ala2 for DPP-4 resistance, Gln8, Ala15, Leu27) that slow enzymatic breakdown, though no plasma half-life has been reported for it in humans.: https://www.bodyhackguide.co/compound/cjc-1295 - CJC-1295 with DACPreclinical / Research peptide CJC-1295 with DAC is the long-acting variant of CJC-1295.: https://www.bodyhackguide.co/compound/cjc-1295-with-dac - GHRP-2Phase 2 GHRP-2 (growth hormone-releasing peptide-2), also known as pralmorelin and KP-102, is a synthetic hexapeptide growth hormone secretagogue that was among the first GHRPs developed in the seminal research of Cyril Bowers and colleagues at Tulane University in the late 1980s and early 1990s.: https://www.bodyhackguide.co/compound/ghrp-2 - GHRP-6Phase 2 GHRP-6 (growth hormone-releasing peptide-6) is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 that binds the ghrelin receptor (GHS-R1a) to stimulate endogenous growth hormone release.: https://www.bodyhackguide.co/compound/ghrp-6 - HexarelinPhase 2 Hexarelin (also called examorelin) is a potent synthetic hexapeptide growth hormone secretagogue with the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2.: https://www.bodyhackguide.co/compound/hexarelin - IGF-1 LR3Phase 2 IGF-1 LR3 (Long R3 IGF-1) is a synthetic analog of human insulin-like growth factor 1 modified at two positions to dramatically extend its serum half-life and amplify its tissue bioactivity compared to native IGF-1.: https://www.bodyhackguide.co/compound/igf-1-lr3 All compounds (https://www.bodyhackguide.co/wiki) ### Compare CJC-1295 with DAC - CJC-1295 with DAC vs CJC-1295 (Mod GRF 1-29): https://www.bodyhackguide.co/compare/cjc-1295-dac-vs-cjc-1295 - Alternatives to CJC-1295 with DAC: https://www.bodyhackguide.co/alternatives-to/cjc-1295-dac All comparisons (https://www.bodyhackguide.co/compare) ### Research tools - Peptide Calculator Reconstitution and syringe units: https://www.bodyhackguide.co/tools/reconstitution - Reconstitution Guide How to mix, step by step: https://www.bodyhackguide.co/guides/how-to-reconstitute-peptides - Nasal Spray Calc mL per actuation: https://www.bodyhackguide.co/tools/intranasal - Half-Life Visualizer Decay curves: https://www.bodyhackguide.co/tools/halflife All articles (https://www.bodyhackguide.co/blog) 08 Questions ## Frequently asked questions What makes DAC different from regular CJC-1295? The DAC (Drug Affinity Complex) is a maleimidopropionic acid (MPA) reactive group at the C-terminus of the peptide. Once injected, it forms a covalent bond with free cysteine residues on circulating serum albumin, effectively turning the small peptide into a long-circulating albumin-peptide conjugate. This extends the half-life from ~30 minutes (non-DAC) to ~8 days (DAC), allowing weekly instead of multiple-times-daily dosing. The trade-off is that DAC produces continuous, non-pulsatile GH elevation rather than the sharp, physiologic GH pulses of the non-DAC form. Why do most clinicians prefer the non-DAC version now? Three main reasons. First, the non-DAC form (MOD-GRF 1-29) preserves the body's natural pulsatile GH release pattern, which most endocrinologists believe is safer and more physiologic. Second, stacking MOD-GRF 1-29 with ipamorelin produces a 3-5x synergistic GH pulse that DAC cannot match (DAC doesn't have effective synergy with daily ghrelin-receptor agonists due to timing mismatch). Third, side effects — edema, carpal tunnel, glucose intolerance — are more common and more severe with sustained GH elevation from DAC. Weekly convenience is DAC's headline advantage; for most users, that doesn't outweigh the physiologic trade-offs. How long does DAC stay in my system after I stop? The half-life is approximately 8 days, so expect 3-4 weeks for full washout after discontinuation. IGF-1 levels gradually return to baseline over 4-6 weeks after the last dose. This long tail has practical implications: if you develop side effects, they resolve slowly; if you need to stop for surgery, plan 2-3 weeks ahead; if you want to switch to MOD-GRF 1-29, wait until full washout before starting the new protocol. It's a major reason some users prefer the more reversible non-DAC form. How much body composition change can I expect? Modestly improved, not dramatic. The benchmark is rhGH in healthy older adults (Blackman 2002, JAMA): 1-3 kg lean mass gain and 2-3 kg fat loss over 6 months. CJC-1295 with DAC produces somewhat less robust changes because it's a secretagogue (depending on pituitary response) rather than direct GH administration. Realistic expectations: 2-5% improvement in lean mass, 5-10% improvement in body fat over 3-6 months with consistent training and nutrition. If you're expecting dramatic physique changes from the peptide alone, you'll be disappointed. The peptide optimizes baseline physiology; you still need the training and diet. Do I need to inject on an empty stomach like with non-DAC? Not strictly. DAC's sustained release profile largely overrides postprandial somatostatin-mediated blunting. You can inject with or without food. However, many experienced users inject pre-bed 2+ hours after dinner, which aligns with natural nocturnal GH pulsing and is convenient for weekly dosing. The fasted-state rule is mandatory for non-DAC (MOD-GRF 1-29); for DAC it's a preference, not a requirement. Can I stack DAC with ipamorelin? Opinions vary. The pharmacologic rationale (synergistic GH pulse from dual pathway activation) is the same as for non-DAC + ipamorelin. However, because DAC already produces sustained GH elevation, adding daily ipamorelin may push pituitary capacity to its limit without proportional benefit, and some clinicians worry about compounding desensitization. A reasonable approach: if using DAC alone and IGF-1 is mid-range but benefit is modest, adding ipamorelin is worth trying. If DAC alone produces adequate IGF-1 rise, adding ipamorelin is probably redundant. Don't stack if you're also experiencing significant DAC-related side effects. Is DAC safe for long-term use? Honestly, the long-term safety data is limited. The Phase 1 trials were short (single-dose and multi-week). Clinical development halted at Phase 2. No multi-year surveillance data exists. Extrapolating from sermorelin (the FDA-approved analog with similar receptor activity), multi-year use appears tolerable in appropriately selected patients. The main long-term concerns are: (1) sustained elevated IGF-1 as a potential pro-tumorigenic signal (Renehan 2004 meta-analysis); (2) glucose dysregulation; (3) receptor desensitization. Use with quarterly lab monitoring, annual cancer screening, and willingness to stop or cycle if signals emerge. Don't assume long-term safety from short-term tolerability. What if I miss a weekly dose? Because DAC has an 8-day half-life, you have 2-3 days of grace built in — missing the weekly dose by a day or two doesn't substantially change your plasma levels. If you remember within 48 hours, take the missed dose and continue your normal schedule. If more than 48 hours late, skip the missed dose and take the next scheduled one — don't double-up. Chronic pattern of missed doses defeats the purpose and indicates DAC may not be the right protocol for you (consider the non-DAC form with daily reminders if adherence is an issue). Can I switch between DAC and non-DAC forms? Yes, but with a washout between. If transitioning DAC → MOD-GRF 1-29: wait 3-4 weeks after last DAC dose for full washout before starting MOD-GRF 1-29, to avoid receptor saturation and prolonged supraphysiologic IGF-1. If transitioning MOD-GRF 1-29 → DAC: you can start DAC within 48 hours of stopping MOD-GRF 1-29 (the non-DAC form clears quickly). Don't use both simultaneously — they target the same receptor and stacking is redundant and increases side effects without benefit. Most clinicians who use both forms do so in different phases of a protocol, not concurrently. How many vendors sell CJC-1295 with DAC, and what does it cost per mg? 3 of the vendors BodyHackGuide tracks list CJC-1295 with DAC (6 listings). Among BodyHackGuide's CJC-1295 with DAC listings recorded as in stock with a milligram count, the lowest price per milligram is $8.00/mg at BioMyst Labs and the median is $10.00/mg. The CJC-1295 with DAC prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a CJC-1295 with DAC listing is dated 27 October 2026. Which vendors have third-party COAs for CJC-1295 with DAC on file at BodyHackGuide? BodyHackGuide holds 22 third-party certificate records for CJC-1295 with DAC, from Half Nattys. No editor has read any of BodyHackGuide's 22 certificate records for CJC-1295 with DAC. The laboratory named on BodyHackGuide's CJC-1295 with DAC certificate records is Freedom Diagnostics Testing, and the newest test date on them is 11 August 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page. Related ## Articles on CJC-1295 with DAC - CJC-1295 and Ipamorelin: A Complete Research Reference Peptides, 1 July 2026: https://www.bodyhackguide.co/blog/cjc-1295-ipamorelin-guide - The Complete Peptide Reconstitution Guide (2026): Ratios, Math, and Common Mistakes Guides, 21 April 2026: https://www.bodyhackguide.co/blog/complete-peptide-reconstitution-guide-2026 Free 2026 Peptide Cheat Sheet (PDF) 38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers. Download Free (https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download) BodyHackGuide (https://www.bodyhackguide.co/) Your biohacking research hub: compound pricing, brain health protocols, dosing tools, and vendor reviews. support@bodyhackguide.co Join our Discord: https://discord.gg/Mhq5UdRYBA r/BodyHackGuide on Reddit: https://reddit.com/r/BodyHackGuide **Affiliate Disclosure:** We rank every vendor on the same public, reproducible methodology (https://www.bodyhackguide.co/vendors/methodology). Full details in our affiliate disclosure (https://www.bodyhackguide.co/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell or ship any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. - Terms: https://www.bodyhackguide.co/terms - Privacy: https://www.bodyhackguide.co/privacy ## Structured data ```json [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "CJC-1295 with DAC" } ] }, { "@context": "https://schema.org", "@type": "Product", "name": "CJC-1295 with DAC", "description": "CJC-1295 with DAC (Drug Affinity Complex) is a modified form of CJC-1295 that incorporates a maleimidopropionic acid (MPA) reactive group at the C-terminus. Once injected, this MPA group forms a covalent thioether bond with free cysteine residues on serum albumin, effectively turning the small peptide into a long-circulating albumin-peptide conjugate. The pharmacokinetic consequence is dramatic. Native GHRH has a half-life of <2 minutes. MOD-GRF 1-29 (CJC-1295 without DAC) has a half-life of ~30 minutes. CJC-1295 with DAC has a half-life of ~8 days and produces sustained IGF-1 elevation for up to 28 days after a single injection (Teichman et al., 2006, J Clin Endocrinol Metab). This makes DAC the weekly-dosing variant: one subcutaneous injection of 1-2 mg per week, typically on the same day each week. Convenience is its headline advantage over MOD-GRF 1-29's 2-3x daily injections. The trade-off is physiologic. DAC produces continuous, non-pulsatile GH elevation rather than the sharp pulses of natural secretion or MOD-GRF 1-29. In Teichman's Phase 1 trial, mean GH levels at 60 mcg/kg rose 2-10 fold above baseline and remained elevated continuously for 6-14 days after a single injection, with IGF-1 rising 1.5-3 fold and staying elevated for up to 28 days with repeated weekly dosing. This is an efficient way to raise IGF-1 but is not how the body normally operates. Clinical development was halted at Phase 2 — ConjuChem Biotechnologies did not publicly detail the reason, though industry commentary has pointed to concerns about sustained non-pulsatile GH elevation, insulin resistance, and the general challenges of bringing a GH-axis drug to market. Tesamorelin (a shorter-acting GHRH analog) became the FDA-approved GHRH analog for HIV-associated lipodystrophy instead. CJC-1295 with DAC is not FDA-approved and is used research-only or through compounding pharmacies. It is the less-favored of the two CJC-1295 forms in modern clinical protocols; most practitioners now prefer MOD-GRF 1-29 (without DAC) stacked with ipamorelin for the more physiologic pulsatile profile. See /compound/cjc-1295 for the non-DAC variant, and our Reconstitution Tool for injection math.", "url": "https://www.bodyhackguide.co/compound/cjc-1295-dac", "image": "https://www.bodyhackguide.co/og-image.png", "brand": { "@type": "Brand", "name": "Research Compound" }, "offers": { "@type": "AggregateOffer", "lowPrice": "34.99", "highPrice": "59.00", "priceCurrency": "USD", "offerCount": "5", "availability": "https://schema.org/InStock", "offers": [ { "@type": "Offer", "price": "34.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://halfnattys.is/product/cjc-w-dac-5mg/?ref=choncho", "seller": { "@type": "Organization", "name": "Half Nattys", "url": "https://halfnattys.is/?ref=choncho" }, "name": "CJC-1295 with DAC 2mg vial" }, { "@type": "Offer", "price": "39.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://biomystlabs.com/product/cjc-w-dac-5mg/?ref=rxtkqorwv", "seller": { "@type": "Organization", "name": "BioMyst Labs", "url": "https://biomystlabs.com" }, "name": "CJC-1295 with DAC 5mg vial" }, { "@type": "Offer", "price": "44.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://biomystlabs.com/product/cjc-w-dac-5mg/?ref=rxtkqorwv", "seller": { "@type": "Organization", "name": "BioMyst Labs", "url": "https://biomystlabs.com" }, "name": "CJC-1295 with DAC 5mg vial" }, { "@type": "Offer", "price": "49.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://halfnattys.is/product/cjc-w-dac-5mg/?ref=choncho", "seller": { "@type": "Organization", "name": "Half Nattys", "url": "https://halfnattys.is/?ref=choncho" }, "name": "CJC-1295 with DAC 5mg vial" }, { "@type": "Offer", "price": "59.00", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://ionpeptide.com/product/cjc-1295-with-dac-5mg/?ref=reddit15", "seller": { "@type": "Organization", "name": "Ion Peptide", "url": "https://ionpeptide.com" }, "name": "CJC-1295 with DAC 5mg vial" } ] } }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "CJC-1295 with DAC", "description": "CJC-1295 with DAC (Drug Affinity Complex) is a modified form of CJC-1295 that incorporates a maleimidopropionic acid (MPA) reactive group at the C-terminus. Once injected, this MPA group forms a covalent thioether bond with free cysteine residues on serum albumin, effectively turning the small peptide into a long-circulating albumin-peptide conjugate. The pharmacokinetic consequence is dramatic. Native GHRH has a half-life of <2 minutes. MOD-GRF 1-29 (CJC-1295 without DAC) has a half-life of ~30 minutes. CJC-1295 with DAC has a half-life of ~8 days and produces sustained IGF-1 elevation for up to 28 days after a single injection (Teichman et al., 2006, J Clin Endocrinol Metab). This makes DAC the weekly-dosing variant: one subcutaneous injection of 1-2 mg per week, typically on the same day each week. Convenience is its headline advantage over MOD-GRF 1-29's 2-3x daily injections. The trade-off is physiologic. DAC produces continuous, non-pulsatile GH elevation rather than the sharp pulses of natural secretion or MOD-GRF 1-29. In Teichman's Phase 1 trial, mean GH levels at 60 mcg/kg rose 2-10 fold above baseline and remained elevated continuously for 6-14 days after a single injection, with IGF-1 rising 1.5-3 fold and staying elevated for up to 28 days with repeated weekly dosing. This is an efficient way to raise IGF-1 but is not how the body normally operates. Clinical development was halted at Phase 2 — ConjuChem Biotechnologies did not publicly detail the reason, though industry commentary has pointed to concerns about sustained non-pulsatile GH elevation, insulin resistance, and the general challenges of bringing a GH-axis drug to market. Tesamorelin (a shorter-acting GHRH analog) became the FDA-approved GHRH analog for HIV-associated lipodystrophy instead. CJC-1295 with DAC is not FDA-approved and is used research-only or through compounding pharmacies. It is the less-favored of the two CJC-1295 forms in modern clinical protocols; most practitioners now prefer MOD-GRF 1-29 (without DAC) stacked with ipamorelin for the more physiologic pulsatile profile. See /compound/cjc-1295 for the non-DAC variant, and our Reconstitution Tool for injection math.", "lastReviewed": "2026-10-02T07:11:00+00:00", "url": "https://www.bodyhackguide.co/compound/cjc-1295-dac", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "CJC-1295 with DAC", "alternateName": [ "CJC w/ DAC", "CJC DAC" ], "description": "CJC-1295 with DAC (Drug Affinity Complex) is a modified form of CJC-1295 that incorporates a maleimidopropionic acid (MPA) reactive group at the C-terminus. Once injected, this MPA group forms a covalent thioether bond with free cysteine residues on serum albumin, effectively turning the small peptide into a long-circulating albumin-peptide conjugate. The pharmacokinetic consequence is dramatic. Native GHRH has a half-life of <2 minutes. MOD-GRF 1-29 (CJC-1295 without DAC) has a half-life of ~30 minutes. CJC-1295 with DAC has a half-life of ~8 days and produces sustained IGF-1 elevation for up to 28 days after a single injection (Teichman et al., 2006, J Clin Endocrinol Metab). This makes DAC the weekly-dosing variant: one subcutaneous injection of 1-2 mg per week, typically on the same day each week. Convenience is its headline advantage over MOD-GRF 1-29's 2-3x daily injections. The trade-off is physiologic. DAC produces continuous, non-pulsatile GH elevation rather than the sharp pulses of natural secretion or MOD-GRF 1-29. In Teichman's Phase 1 trial, mean GH levels at 60 mcg/kg rose 2-10 fold above baseline and remained elevated continuously for 6-14 days after a single injection, with IGF-1 rising 1.5-3 fold and staying elevated for up to 28 days with repeated weekly dosing. This is an efficient way to raise IGF-1 but is not how the body normally operates. Clinical development was halted at Phase 2 — ConjuChem Biotechnologies did not publicly detail the reason, though industry commentary has pointed to concerns about sustained non-pulsatile GH elevation, insulin resistance, and the general challenges of bringing a GH-axis drug to market. Tesamorelin (a shorter-acting GHRH analog) became the FDA-approved GHRH analog for HIV-associated lipodystrophy instead. CJC-1295 with DAC is not FDA-approved and is used research-only or through compounding pharmacies. It is the less-favored of the two CJC-1295 forms in modern clinical protocols; most practitioners now prefer MOD-GRF 1-29 (without DAC) stacked with ipamorelin for the more physiologic pulsatile profile. See /compound/cjc-1295 for the non-DAC variant, and our Reconstitution Tool for injection math.", "activeIngredient": "CJC-1295 with DAC", "administrationRoute": "Subcutaneous", "mechanismOfAction": "CJC-1295 with DAC has the same pharmacodynamic mechanism as the non-DAC variant (GHRH receptor agonism on pituitary somatotrophs) but radically different pharmacokinetics. Albumin conjugation - the central pharmacokinetic feature The MPA (maleimidopropionic acid) group is highly reactive toward free thiol groups Serum albumin contains one free cysteine (Cys-34) per molecule Within hours of SC injection, CJC-1295 DAC forms a covalent thioether bond with Cys-34 on serum albumin The conjugate circulates for the full albumin half-life (~20 days) Effective drug half-life: ~8 days (shorter than albumin because GHRH portion is slowly cleaved/metabolized) Sustained GHRH-receptor activation Because the albumin-bound conjugate keeps GHRH-active peptide in circulation for days, the pituitary GHRH receptor is continuously exposed to ligand rather than to brief, widely spaced pulses. Critically, this does not abolish pulsatile GH release: in the controlled pharmacodynamic work, pulsatile GH secretion persisted during continuous stimulation with CJC-1295 (Ionescu & Frohman, 2006, J Clin Endocrinol Metab). What shifts is the baseline - DAC raises trough (basal) and mean GH concentrations while the underlying pulse frequency is largely preserved. The practical consequences: Higher basal and mean GH, with pulsatility retained rather than eliminated A sustained IGF-1 plateau rather than the sharp IGF-1 swings of short-acting secretagogues A theoretical risk of partial receptor desensitization with chronic, continuous exposure Pharmacokinetic profile (Teichman Phase 1 data) Single 60 mcg/kg SC dose: GH levels: 2-10x baseline, sustained for 6-14 days IGF-1: 1.5-3x baseline, sustained for up to 28 days with repeated weekly dosing IGFBP-3 proportionally elevated No direct ghrelin-receptor activity DAC does not bind GHS-R1a. If stacking with ipamorelin is desired, the two must be dosed separately - DAC weekly, ipamorelin daily. Many practitioners skip ipamorelin when using DAC because the sustained GH elevation already approaches pituitary capacity. Downstream IGF-1 axis effects Hepatic JAK2/STAT5 signaling produces sustained IGF-1 mRNA transcription IGFBP-3 rises proportionally (binds 90% of circulating IGF-1) Free (bioactive) IGF-1 rises modestly Tissue IGF-1 (muscle, bone, cartilage) rises more substantially What's different vs MOD-GRF 1-29 (without DAC) This is why modern protocols favor the non-DAC form despite its inconvenience.", "dosageForm": "vial", "legalStatus": "Not approved for human use (research chemical)", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What makes DAC different from regular CJC-1295?", "acceptedAnswer": { "@type": "Answer", "text": "The DAC (Drug Affinity Complex) is a maleimidopropionic acid (MPA) reactive group at the C-terminus of the peptide. Once injected, it forms a covalent bond with free cysteine residues on circulating serum albumin, effectively turning the small peptide into a long-circulating albumin-peptide conjugate. This extends the half-life from ~30 minutes (non-DAC) to ~8 days (DAC), allowing weekly instead of multiple-times-daily dosing. The trade-off is that DAC produces continuous, non-pulsatile GH elevation rather than the sharp, physiologic GH pulses of the non-DAC form." } }, { "@type": "Question", "name": "Why do most clinicians prefer the non-DAC version now?", "acceptedAnswer": { "@type": "Answer", "text": "Three main reasons. First, the non-DAC form (MOD-GRF 1-29) preserves the body's natural pulsatile GH release pattern, which most endocrinologists believe is safer and more physiologic. Second, stacking MOD-GRF 1-29 with ipamorelin produces a 3-5x synergistic GH pulse that DAC cannot match (DAC doesn't have effective synergy with daily ghrelin-receptor agonists due to timing mismatch). Third, side effects — edema, carpal tunnel, glucose intolerance — are more common and more severe with sustained GH elevation from DAC. Weekly convenience is DAC's headline advantage; for most users, that doesn't outweigh the physiologic trade-offs." } }, { "@type": "Question", "name": "How long does DAC stay in my system after I stop?", "acceptedAnswer": { "@type": "Answer", "text": "The half-life is approximately 8 days, so expect 3-4 weeks for full washout after discontinuation. IGF-1 levels gradually return to baseline over 4-6 weeks after the last dose. This long tail has practical implications: if you develop side effects, they resolve slowly; if you need to stop for surgery, plan 2-3 weeks ahead; if you want to switch to MOD-GRF 1-29, wait until full washout before starting the new protocol. It's a major reason some users prefer the more reversible non-DAC form." } }, { "@type": "Question", "name": "How much body composition change can I expect?", "acceptedAnswer": { "@type": "Answer", "text": "Modestly improved, not dramatic. The benchmark is rhGH in healthy older adults (Blackman 2002, JAMA): 1-3 kg lean mass gain and 2-3 kg fat loss over 6 months. CJC-1295 with DAC produces somewhat less robust changes because it's a secretagogue (depending on pituitary response) rather than direct GH administration. Realistic expectations: 2-5% improvement in lean mass, 5-10% improvement in body fat over 3-6 months with consistent training and nutrition. If you're expecting dramatic physique changes from the peptide alone, you'll be disappointed. The peptide optimizes baseline physiology; you still need the training and diet." } }, { "@type": "Question", "name": "Do I need to inject on an empty stomach like with non-DAC?", "acceptedAnswer": { "@type": "Answer", "text": "Not strictly. DAC's sustained release profile largely overrides postprandial somatostatin-mediated blunting. You can inject with or without food. However, many experienced users inject pre-bed 2+ hours after dinner, which aligns with natural nocturnal GH pulsing and is convenient for weekly dosing. The fasted-state rule is mandatory for non-DAC (MOD-GRF 1-29); for DAC it's a preference, not a requirement." } }, { "@type": "Question", "name": "Can I stack DAC with ipamorelin?", "acceptedAnswer": { "@type": "Answer", "text": "Opinions vary. The pharmacologic rationale (synergistic GH pulse from dual pathway activation) is the same as for non-DAC + ipamorelin. However, because DAC already produces sustained GH elevation, adding daily ipamorelin may push pituitary capacity to its limit without proportional benefit, and some clinicians worry about compounding desensitization. A reasonable approach: if using DAC alone and IGF-1 is mid-range but benefit is modest, adding ipamorelin is worth trying. If DAC alone produces adequate IGF-1 rise, adding ipamorelin is probably redundant. Don't stack if you're also experiencing significant DAC-related side effects." } }, { "@type": "Question", "name": "Is DAC safe for long-term use?", "acceptedAnswer": { "@type": "Answer", "text": "Honestly, the long-term safety data is limited. The Phase 1 trials were short (single-dose and multi-week). Clinical development halted at Phase 2. No multi-year surveillance data exists. Extrapolating from sermorelin (the FDA-approved analog with similar receptor activity), multi-year use appears tolerable in appropriately selected patients. The main long-term concerns are: (1) sustained elevated IGF-1 as a potential pro-tumorigenic signal (Renehan 2004 meta-analysis); (2) glucose dysregulation; (3) receptor desensitization. Use with quarterly lab monitoring, annual cancer screening, and willingness to stop or cycle if signals emerge. Don't assume long-term safety from short-term tolerability." } }, { "@type": "Question", "name": "What if I miss a weekly dose?", "acceptedAnswer": { "@type": "Answer", "text": "Because DAC has an 8-day half-life, you have 2-3 days of grace built in — missing the weekly dose by a day or two doesn't substantially change your plasma levels. If you remember within 48 hours, take the missed dose and continue your normal schedule. If more than 48 hours late, skip the missed dose and take the next scheduled one — don't double-up. Chronic pattern of missed doses defeats the purpose and indicates DAC may not be the right protocol for you (consider the non-DAC form with daily reminders if adherence is an issue)." } }, { "@type": "Question", "name": "Can I switch between DAC and non-DAC forms?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, but with a washout between. If transitioning DAC → MOD-GRF 1-29: wait 3-4 weeks after last DAC dose for full washout before starting MOD-GRF 1-29, to avoid receptor saturation and prolonged supraphysiologic IGF-1. If transitioning MOD-GRF 1-29 → DAC: you can start DAC within 48 hours of stopping MOD-GRF 1-29 (the non-DAC form clears quickly). Don't use both simultaneously — they target the same receptor and stacking is redundant and increases side effects without benefit. Most clinicians who use both forms do so in different phases of a protocol, not concurrently." } }, { "@type": "Question", "name": "How many vendors sell CJC-1295 with DAC, and what does it cost per mg?", "acceptedAnswer": { "@type": "Answer", "text": "3 of the vendors BodyHackGuide tracks list CJC-1295 with DAC (6 listings). Among BodyHackGuide's CJC-1295 with DAC listings recorded as in stock with a milligram count, the lowest price per milligram is $8.00/mg at BioMyst Labs and the median is $10.00/mg. The CJC-1295 with DAC prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a CJC-1295 with DAC listing is dated 27 October 2026." } }, { "@type": "Question", "name": "Which vendors have third-party COAs for CJC-1295 with DAC on file at BodyHackGuide?", "acceptedAnswer": { "@type": "Answer", "text": "BodyHackGuide holds 22 third-party certificate records for CJC-1295 with DAC, from Half Nattys. No editor has read any of BodyHackGuide's 22 certificate records for CJC-1295 with DAC. The laboratory named on BodyHackGuide's CJC-1295 with DAC certificate records is Freedom Diagnostics Testing, and the newest test date on them is 11 August 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 273 compound profiles, interactive dosing calculators, vendor price comparisons, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. We earn a commission on purchases through some of our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] ```